Arm A (Cap+Bev / Eve+Exe) (N = 39) | Arm B (Eve+Exe / Cap+Bev) (N = 38) | |
---|---|---|
Age [years], median (range) | 64.4 (47.0–83.6) | 65.9 (49.8–86.0) |
Ethnicity, n (%) | ||
Caucasian | 38 (97.4%) | 37 (97.4%) |
Asian | 1 (2.6%) | 1 (2.6%) |
BMI [kg/m2], median (quartiles) | 25.6 (22.5–28.4) | 24.9 (22.7–31.1) |
ECOG Performance Status, n (%) | ||
0 | 19 (48.7%) | 17 (44.7%) |
1 | 19 (48.7%) | 20 (52.6%) |
2 | 1 (2.6%) | 1 (2.6%) |
Menopausal status, n (%) | ||
Postmenopausal | 39 (100%) | 38 (100%) |
Concomitant diseases, n (%) | ||
Yes | 33 (84.6%) | 35 (92.1%) |
No | 6 (15.4%) | 3 (7.9%) |
Visceral disease or local relapse, n (%) | 27 (69.2%) | 26 (68.4%) |
Non-visceral disease, n (%) | 12 (30.8%) | 12 (31.6%) |
Metastatic sitesa, n (%) | ||
Bone | 28 (71.8%) | 29 (76.3%) |
Liver | 15 (38.5%) | 16 (42.1%) |
Lung | 8 (20.5%) | 10 (26.3%) |
Histology of tumor, n (%) | ||
Invasive ductal | 27 (69.2%) | 24 (63.2%) |
Invasive lobular | 7 (17.9%) | 12 (31.6%) |
Inflammatory cancer | 1 (2.6%) | 0 |
Not otherwise specified | 4 (10.3%) | 2 (5.3%) |
DFIb [years], median (quartiles) | 4.7 (1.4–10.9) | 5.0 (1.3–8.2) |
Time since initial diagnosis [years], median (quartiles) | 9.6 (3.6–13.0) | 6.6 (2.5–10.0) |
Time since first relapsec [years], median (quartiles) | 8.4 (0.6–23.4) | 5.1 (1.5–15.1) |
Any prior adjuvant chemotherapy, n (%) | 22 (56.4%) | 28 (73.7%) |
Prior adjuvant taxane and/or anthracycline therapy, n (%) | 22 (56.4%) | 26 (68.4%) |
Number of prior palliative endocrine therapies, n (%) | ||
1 | 10 (25.6%) | 13 (34.2%) |
2 | 11 (28.2%) | 10 (26.3%) |
3 | 1 (2.6%) | 0 |